Olaparib
Olaparib 300 mg BID
300 mg · Single arm
recurrent IDH-mutant high-grade glioma (n = 35)
median OS: 15.9 months
OLAGLI · NCT03561870
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
1 arm has a reported figure in this set.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.